INTRODUCTION {#s1}
============

Named for the abnormal curvature of long bones seen in most patients, campomelic dysplasia (CMPD; Greek: *campto* = bent and *melia* = *limb*; OMIM \#114290) is a rare skeletal dysplasia reported in 1:40,000 to 1:80,000 births ([@MCS002766ANTC29]). Patients frequently present with bowing of the long bones, Pierre Robin sequence (PRS; i.e., cleft palate, glossoptosis, and micrognathia), tracheobronchomalacia, sex reversal in genotypic males, and 11 pairs of gracile ribs ([@MCS002766ANTC18]; [@MCS002766ANTC29]). Central nervous system (CNS) involvement may include kyphoscoliosis, hypoplastic olfactory tract, cerebral atrophy, and ventriculomegaly ([@MCS002766ANTC18]; [@MCS002766ANTC20]). A variant of CMPD, acampomelic campomelic dysplasia (ACMPD), is seen in ∼10% of cases and lacks involvement of long bones ([@MCS002766ANTC33]). CMPD is lethal in the neonatal period, but patients with less severe phenotypes may survive ([@MCS002766ANTC19]).

Mutations and chromosomal arrangements that affect expression and/or activity of *SOX9* are implicated in CMPD ([@MCS002766ANTC29]). Several cases of CMPD/ACMPD due to translocations upstream of *SOX9* have been reported ([@MCS002766ANTC33]). Here, we report a 3-mo-old patient found to have skeletal anomalies on prenatal ultrasound and unbalanced translocation t(6;17) (p21.1;q24.3) with deletions on prenatal genetic testing. Located 2.3 Mb upstream of *SOX9*, the translocation configures a previously unreported breakpoint cluster on Chromosome 17. Postnatal radiographs, clinical features, and genetic testing were consistent with CMPD. This patient came to the attention of our pediatric neurosurgical service because of acquired diffuse ventriculomegaly at 2 mo of age. Additionally, respiratory compromise, likely due to tracheobronchomalacia, was noted at this time. This case demonstrates the clinical, radiographic, and genetic features of CMPD, introduces a novel breakpoint, and suggests a new cluster of noncoding region that likely controls *SOX9* expression.

RESULTS {#s2}
=======

Clinical Presentation and Treatment {#s2a}
-----------------------------------

The patient was born at 39 wk of gestation to a G~3~P~2012~ mother in a nonconsanguineous marriage who had a previous chemical pregnancy. Ultrasound obtained at 20 wk of gestation showed bowed femurs and right tibia, increased nuchal thickness (6.2 mm), and female external genitalia. No intracranial abnormalities were identified. Amniocentesis was performed at 21 wk of gestation, revealing a normal level of α-fetoprotein (5748 ng/ml; Yale New Haven Hospital Laboratory). Cytogenetic analysis on cultured amniocytes was then pursued. The parents were counseled on the likelihood of the fetus having CMPD given radiographic and genetic findings (discussed in detail under Genetic Analysis); a decision was reached to continue gestation to term.

The patient was delivered by elective cesarean section because of breech presentation. She demonstrated respiratory distress at birth, requiring immediate intubation and admission to the neonatal intensive care unit. She additionally demonstrated a Veau 2 cleft palate, mild retrognathia, and hypertelorism. Shortly after delivery, magnetic resonance imaging (MRI) of the head (protocoled to study the skull base, sinonasal, and facial regions) demonstrated craniofacial defects including cleft hard palate, leftward deviation of nasal septum, hypoplastic mandible and maxilla, and 45° vertical angulation of the skull base. No intracranial abnormalities were noted ([Fig. 1](#MCS002766ANTF1){ref-type="fig"}A,C,E). MRI of the spine was notable for hypoplastic C6 vertebral body, exaggerated cervical lordosis, and exaggerated thoracic kyphosis resulting in severe canal stenosis at T1--4 ([Fig. 2](#MCS002766ANTF2){ref-type="fig"}). A pelvic ultrasound showed a normal appearing uterus and a hypoplastic right ovary; the left ovary was not visualized. A subsequent skeletal X-ray survey revealed angulated left femoral shaft, hypoplastic pubic bones, and absent ossification of the right talus ([Fig. 3](#MCS002766ANTF3){ref-type="fig"}). After 31 d in the intensive care unit, the patient was discharged with plans for multidisciplinary outpatient management including neurosurgical follow-up.

![Acquired diffuse ventriculomegaly as a manifestation of campomelic dysplasia. At birth the patient had no radiographic evidence of ventriculomegaly (see axial T2-weighted, reformatted coronal, and sagittal FLAIR images in *A*,*C*,*E*). At 2 mo old she had lateral, third, and fourth ventriculomegaly but no clinical evidence of increased intracranial pressure (ICP) (*B*,*D*,*F*).](MCS002766Ant_F1){#MCS002766ANTF1}

![Spinal involvement in campomelic dysplasia. Our patient demonstrated exaggerated cervical lordosis and thoracic kyphosis. Notice moderate-to-severe stenosis of the spinal canal from T1/2 to T3/4 on the sagittal isotropic T2-weighted image. Image artifact from bed support is present.](MCS002766Ant_F2){#MCS002766ANTF2}

![Skeletal features of campomelic dysplasia. Skeletal involvement in CMPD may include (*A*) pairs of gracile ribs, exaggerated lordosis of the cervical spine (often associated with hypoplastic cervical vertebral bodies), and (*B*) shortening and angulation of long bones (usually of the lower extremities).](MCS002766Ant_F3){#MCS002766ANTF3}

At 2 mo of age the patient was readmitted for lethargy and acute respiratory distress. Chest X-ray showed focal basilar consolidations. A head ultrasound was notable for ventriculomegaly, for which neurosurgery was consulted. On neurological examination, the patient spontaneously opened eyes with briskly reactive pupils, moved all extremities to light stimulation, exhibited flat and soft fontanels, and had a head circumference of 40 cm (90th percentile). There were no clinical signs of increased intracranial pressure (ICP). Subsequent MRI brain (protocoled with a T2 cine flow study) revealed globally dilated ventricles with marked prominence of the basal, prepontine, and suprasellar cisterns, enlarged bifrontal extra-axial spaces, development of a mega cisterna magna, and patent flow around the foramen magnum ([Fig. 1](#MCS002766ANTF1){ref-type="fig"}B,D,F). Computerized tomography (CT) evaluation of the spine revealed gracile ribs, narrowed spinal canal at the cervicothoracic junction, and narrowed thoracic cage. The patient\'s neurologic exam was monitored over several days for signs of increased ICP with plans for a possible external ventricular drain, but she showed no such signs. She required mechanical ventilation and later tracheostomy for ventilator support. Surveillance MRI obtained at 3 mo of age revealed worsening ventriculomegaly in spite of the patient showing no clinical signs of increased ICP ([Fig. 4](#MCS002766ANTF4){ref-type="fig"}).

![Worsening acquired ventriculomegaly in CMPD. At 3 mo of age, surveillance (*A*) axial, (*B*) coronal, and (*C*) sagittal T2-weighted MRI demonstrate worsening ventriculomegaly, although the patient showed no clinical signs of increased intracranial pressure (ICP).](MCS002766Ant_F4){#MCS002766ANTF4}

Genetic Analysis {#s2b}
----------------

All procedures reported comply with Yale University\'s Human Investigation Committee and Human Research Protection Program. Written consent from both parents was obtained prior to genetic testing. All reported genomic coordinates reference the human genome assembly (GRCh37/hg19).

Fluorescence in situ hybridization (FISH; using probes for RB1 at 13q14, D21S259, Xcen, Ycen, and D18Z1; Vysis Inc.) of cultured amniocytes obtained at 21 wk of gestation demonstrated normal Chromosomes 13, 18, 21, X, and Y and the presence of the SRY locus. It additionally revealed an apparently balanced translocation between chromosomal bands 6p21.1 and 17q24: 46, XY, t(6;17) (p21.1;q24.3) ([Fig. 5](#MCS002766ANTF5){ref-type="fig"}). Concurrent array comparative genomic hybridization (aCGH; Agilent 180K) analysis on DNA extracted from cultured amniocytes was performed. It showed an XY male with a 125 kb deletion at 6p21.1 (Chr 6:41,621,953--41,746,502) and a 97 kb deletion at 17q24.3 (Chr 17:67,666,390-67,762,983). The deletion at 6p21.1 includes *MDFI*, *TFEB*, *PGC*, and *FRS3*; the deletion at 17q24.3 contains no genes and is ∼2.3 Mb upstream of *SOX9* (Chr 17:70,117,161--70,122,561). Contrasting results between FISH and array comparative genomic hybridization (aCGH) ascertained an unbalanced translocation. Karyotype and aCGH (using Agilent 400K) of cultured stimulated peripheral lymphocytes from proband\'s mother revealed a normal female complement. Karyotype and aCGH (using Agilent 180K) of cultured stimulated peripheral lymphocytes from proband\'s father revealed a normal male complement.

![Ideogram and karyogram of patient. (*A*) Ideogram and (*B*) karyogram demonstrating the unbalanced translocation in our patient. At the *bottom* of *B* is a schema demonstrating the approximated relation of our patient\'s breakpoint site on Chromosome 17 to previously reported breakpoint sites in CMPD. ‡ denotes chromosomes with translocated segments in our patient. (Used: Hiller B, Bradtke J, Balz H, Rieder H \[2004\]: "CyDAS Online Analysis Site"; <http://www.cydas.org/OnlineAnalysis/>.)](MCS002766Ant_F5){#MCS002766ANTF5}

The absence of chromosomal rearrangements on genetic testing of parents suggested that the unbalanced translocation in the proband most likely occurred de novo. Postnatal FISH (Cytocell Inc.) and cytogenetics using peripheral blood samples from the proband corroborated results of the prenatal genetic studies.

When the patient was readmitted at 2 mo of age, a peripheral blood sample was obtained for high-throughput whole-exome sequencing (WES; using Roche/Nimblegen MedExome and Illumina HiSeq platform). It showed that 98.8% of targeted bases had eight or more independent reads, and 98.6% had 15 or more (see [Supplemental Table 4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002766/-/DC1) for WES coverage metrics). No pathogenic variants were identified in *SOX9*, and the deletion at 17q24.3 was not present, suggesting that CMPD in our patient was likely due to the unbalanced translocation at a noncoding locus on Chromosome 17 (see [Table 1](#MCS002766ANTTB1){ref-type="table"} for genetic variants).

###### 

Germline variants identified in the patient

  Gene                           Chr-pos-ref-alt        HGVS alterations   Variant type   Predicted effect (PolyPhen)   MetaSVM   CADD   dbSNP         ExAC            pLI    mis_Z
  ------------------------------ ---------------------- ------------------ -------------- ----------------------------- --------- ------ ------------- --------------- ------ -------
  Heterozygous variants                                                                                                                                                       
   *LAMB2*                       3-55369293-GA-G        p.Ser1169fs        fs_deletion    N/A                           N/A       N/A    N/A           N/A             0.00   1.61
   *TRIM4*                       7-53226946-GCTGA-G     p.Ser194fs         fs_deletion    N/A                           N/A       N/A    N/A           N/A             0.00   0.29
   *BECN1*                       17-40963699-GC-G       p.Gly386fs         fs_deletion    N/A                           N/A       N/A    N/A           N/A             1.00   1.57
   *SPAG17*                      1-114304570-T-TATTTG   p.Tyr1296fs        fs_insertion   N/A                           N/A       N/A    N/A           N/A             0.00   −2.39
   *DIMT1*                       5-14031721-T-TAA       p.Val207fs         fs_insertion   N/A                           N/A       N/A    N/A           N/A             0.00   0.36
   *SLC27A6*                     5-19369362-G-A         c.1454+1G\>A       Splicing       N/A                           N/A       26.1   rs779289426   4.14 × 10^−5^   0.00   −1.24
   *PAPPA2*                      1-19207800-C-T         p.Gln443\*         Stop-gain      N/A                           N/A       33.0   N/A           N/A             0.00   0.13
   *ADRA2B*                      2-119993667-C-T        p.Trp112\*         Stop-gain      N/A                           N/A       36.0   N/A           N/A             0.00   0.52
   *MRPL44*                      2-33349186-C-T         p.Gln106\*         Stop-gain      N/A                           N/A       36.0   rs769072268   3.30 × 10^−5^   0.00   −0.11
   *UGT2A3*                      4-20109056-A-T         p.Leu121\*         Stop-gain      N/A                           N/A       28.1   N/A           N/A             0.00   −3.21
   *FGF5*                        4-40963699-T-A         p.Leu3\*           Stop-gain      N/A                           N/A       36.0   N/A           N/A             0.00   −0.58
   *H6PD*                        1-179143220-C-T        p.Ala153Val        Missense       D                             D         31.0   N/A           N/A             0.00   −0.73
   *GBA*                         1-69970145-G-A         p.Pro358Leu        Missense       D                             D         27.6   N/A           N/A             0.03   2.06
   *CANX*                        5-39307740-C-T         p.Pro279Leu        Missense       D                             D         32.0   rs769363661   4.12 × 10^−5^   0.86   0.92
   *GAS1*                        9-60498743-G-C         p.Arg45Gly         Missense       D                             D         25.9   N/A           N/A             0.62   4.27
   *CSRP3*                       11-19207800-G-A        p.Ser126Leu        Missense       B                             D         23.7   N/A           N/A             0.00   −0.66
   *GCH1*                        14-55369293-G-C        p.Pro30Arg         Missense       B                             D         16.3   N/A           N/A             0.94   2.91
   *SMPD3*                       16-68404920-C-T        p.Val389Ile        Missense       P                             D         22.6   rs757669112   4.97 × 10^−5^   0.66   0.34
   *DNM2*                        19-10939884-T-C        p.Val744Ala        Missense       B                             D         11.8   rs777609224   2.49 × 10^−5^   1.00   4.61
   *DOK5*                        20-53226946-G-A        p.Gly99Arg         Missense       D                             D         34.0   N/A           N/A             0.04   1.18
   *PITHD1*                      1-38702298-C-G         p.Thr164Arg        Missense       B                             T         23.0   rs763501501   3.31 × 10^−5^   0.10   1.58
   *DNAJB4*                      1-99506417-C-T         p.Arg47Trp         Missense       P                             T         24.8   rs756468720   1.67 × 10^−5^   0.84   0.13
   *HENMT1*                      1-89561562-A-C         p.Leu347Arg        Missense       P                             T         22.5   rs755233826   8.24 × 10^−6^   0.00   −0.42
   *METTL18*                     1-4661109-A-G          p.Val334Ala        Missense       B                             T         22.7   N/A           N/A             0.03   −1.40
   *PTPN14*                      1-61040701-C-T         p.Arg8His          Missense       P                             T         34.0   N/A           N/A             0.99   1.53
   *FMNL2*                       2-27087562-G-T         p.Ser160Ile        Missense       B                             T         20.4   rs866373641   N/A             1.00   1.50
   *IQCA1*                       2-23518359-C-T         p.Arg220His        Missense       B                             T         25.6   rs563978762   1.33 × 10^−5^   0.00   −0.99
   *STX19*                       3-57700600-T-C         p.Tyr151Cys        Missense       D                             T         24.7   rs759950914   8.24 × 10^−6^   0.00   −1.93
   *RPN1*                        3-846041-G-A           p.Ala566Val        Missense       B                             T         23.0   rs754321104   3.30 × 10^−5^   0.66   0.87
   *PLXND1*                      3-68404920-G-A         p.Ala562Val        Missense       P                             T         22.7   rs746020904   2.43 × 10^−5^   1.00   4.48
   *YEATS2*                      3-8167903-C-T          p.His1228Tyr       Missense       B                             T         25.2   rs749637060   1.66 × 10^−5^   1.00   −0.81
   *FAT4*                        4-72725470-C-T         p.Pro4564Leu       Missense       P                             T         27.9   N/A           N/A             1.00   −0.32
   *C7*                          5-10939884-C-A         p.Asp453Glu        Missense       P                             T         25.2   N/A           N/A             0.00   −2.57
   *MAP1B*                       5-15276648-G-A         p.Asp1758Asn       Missense       B                             T         24.1   N/A           N/A             1.00   2.04
   *DNAH8*                       6-52793840-A-T         p.Lys220Ile        Missense       P                             T         23.2   N/A           N/A             0.00   −0.94
   *ZNF483*                      9-61919093-C-T         p.Ala452Val        Missense       B                             T         24.4   rs751071638   1.66 × 10^−5^   0.41   1.89
   *MYPN*                        10-35808610-C-T        p.Ser1005Phe       Missense       B                             T         25.6   rs748628394   8.24 × 10^−6^   0.07   −0.35
   *OR51D1*                      11-4661109-C-T         p.Pro30Leu         Missense       D                             T         24.6   N/A           N/A             0.00   −2.06
   *VWCE*                        11-61040701-A-G        p.Phe557Leu        Missense       B                             T         23.7   rs752514073   N/A             0.00   0.38
   *TRIM29*                      11-119993667-G-C       p.Pro477Arg        Missense       P                             T         23.7   N/A           N/A             0.00   0.38
   *INTS13*                      12-27087562-A-G        p.Val76Ala         Missense       B                             T         26.3   N/A           N/A             N/A    N/A
   *PDS5B*                       13-33349186-G-A        p.Arg1447Gln       Missense       D                             T         24.1   N/A           N/A             1.00   3.56
   *CDH24*                       14-23518359-T-G        p.Ser613Arg        Missense       D                             T         22.7   N/A           N/A             0.00   2.75
   *EXOC5*                       14-57700600-C-T        p.Gly239Asp        Missense       B                             T         21.9   rs753219587   2.49 × 10^−5^   1.00   1.36
   *CHTF18*                      16-846041-G-A          p.Arg807His        Missense       B                             T         23.1   rs756795078   2.61 × 10^−5^   N/A    N/A
   *PFAS*                        17-8167903-G-A         p.Arg678His        Missense       D                             T         34.0   rs772566332   4.99 × 10^−5^   0.00   0.80
   *SPECC1*                      17-20109056-C-A        p.Ala565Asp        Missense       P                             T         22.8   N/A           N/A             0.11   −1.11
   *RAB37*                       17-72725470-G-A        p.Gly50Ser         Missense       P                             T         23.9   rs753157903   1.65 × 10^−5^   0.00   0.12
   *CC2D1A*                      19-14031721-G-A        p.Val543Met        Missense       D                             T         25.2   N/A           N/A             0.00   0.52
   *NOTCH3*                      19-15276648-G-A        p.Arg1873Cys       Missense       D                             T         33.0   rs749429793   8.37 × 10^−6^   0.21   4.79
   *HAPLN4*                      19-19369362-C-G        p.Asp263His        Missense       D                             T         28.3   N/A           N/A             0.03   2.94
   *ECH1*                        19-39307740-G-A        p.Arg185Trp        Missense       D                             T         33.0   N/A           N/A             0.00   0.00
   *ZNF766*                      19-52793840-A-C        p.Thr266Pro        Missense       D                             T         23.1   rs772342873   2.51 × 10^−5^   0.00   −1.10
   *CDH4*                        20-60498743-T-C        p.Phe537Leu        Missense       B                             T         21.6   rs767012233   8.30 × 10^−6^   0.97   2.39
   *ARFGAP1*                     20-61919093-C-G        p.Ser371Arg        Missense       D                             T         28.4   rs756425439   4.07 × 10^−5^   0.02   −0.30
   *MCM5*                        22-35808610-A-C        p.Ile343Leu        Missense       B                             T         24.5   rs773193463   8.43 × 10^−6^   0.56   1.74
  Homozygous variants                                                                                                                                                         
   *SLAIN1*                      13-78272267-T-TGG      p.Ala73fs          fs_insertion   N/A                           N/A       N/A    rs201380414   0               0.96   1.19
  X-linked hemizygous variants                                                                                                                                                
   *RS1*                         X-18665373-C-G         p.Gln88His         Missense       D                             D         19.9   rs201680258   3.00 × 10^−4^   0.89   1.51
   *SHROOM2*                     X-9914844-C-T          p.Ala1573Val       Missense       P                             T         24.6   rs767591095   4.10 × 10^−5^   0.01   −1.23

HGVS, Human Genome Variation Society; CADD, Combined Annotation Dependent Depletion; N/A, not available; fs, frameshift; PolyPhen: "B"enign, "D"amaging, "P"otentially/probably damaging; MetaSVM: "D"eleterious, "T"olerated.

DISCUSSION {#s3}
==========

We present a patient with CMPD with skeletal, CNS, pulmonary, and genitourinary involvement due to an unbalanced t(6;17) (p21.1;q24.3). Bowing of the long bones of the lower extremities and increased nuchal thickness on second trimester ultrasound study raised suspicion for a chromosomal abnormality in this patient. Prenatal genetic testing revealed 46, XY, t(6;17) (p21.1;q24.3) with a 125-kb deletion on Chromosome 6 and a 97-kb deletion on Chromosome 17, demonstrating a novel breakpoint 2.3 Mb upstream of *SOX9* ([@MCS002766ANTC36]; [@MCS002766ANTC33]). Postnatal WES revealed no pathogenic variants of *SOX9*, suggesting that the unbalanced translocation may be related to CMPD with sex reversal in our patient*.* At 2 mo of age, she had developed progressive communicating ventriculomegaly with normal ICP.

*SOX9,* located at 17q24.3, is the only gene with known pathogenic variants that cause CMPD ([@MCS002766ANTC6]; [@MCS002766ANTC27]). SOX9 belongs to the Sry-related high-mobility group (HMG) of transcriptional regulators and is involved in chrondrogenesis, craniofacial development, male sex determination, and neural stem cell development ([@MCS002766ANTC2]; [@MCS002766ANTC5]; [@MCS002766ANTC26]; [@MCS002766ANTC15]; [@MCS002766ANTC27]).

We identified a de novo unbalanced translocation associated with this case of CMPD. De novo translocations involving 17q24.3--25.1 represent \<5% of cases of CMPD ([@MCS002766ANTC29]). Reported translocations upstream of *SOX9* include t(1;17), t(2;17), t(4;17), t(5;17), t(6;17), t(7;17), t(9;17), t(10;17), t(12;17), t(13;17), t(17;20), and t(17;22) ([@MCS002766ANTC39]; [@MCS002766ANTC28]; [@MCS002766ANTC7]; [@MCS002766ANTC32]; [@MCS002766ANTC22]; [@MCS002766ANTC36]; [@MCS002766ANTC25]; [@MCS002766ANTC37]; [@MCS002766ANTC24]; [@MCS002766ANTC10]; [@MCS002766ANTC31]; [@MCS002766ANTC16]; [@MCS002766ANTC6]; [@MCS002766ANTC20]). Our patient had t(6;17) which has been reported in two previous cases. [@MCS002766ANTC36] reported a patient who demonstrated PRS, dysplastic iliac wings and femur, closed cranial sutures, and external female genitalia. Cytogenetics revealed 46, XY, t(6;17) (q14;q24) in this patient. [@MCS002766ANTC33] reported an infant who presented with PRS, cervical spine deformities, hypoplastic scapulae, external female genitalia, and no involvement of the long bones. Genetic analysis revealed a 46, XY, t(6;17) (q25;q24) in this case of ACMPD. Our patient had the breakpoint at (p21.1;q24.3) with a 125-kb deletion at 6p21.1 (including *MDF1*, *TFEB*, *PGC*, and *FRS3*) and a 97-kb deletion at 17q24.3, which contains no genes. In silico analyses of WES data identified a 74-kb deletion at 6p21.1 (6:41,691,198--41,765,585) that includes *TFEB*, *PGC*, *FRS3*, *PRICKLE4*, *TOMM6*. There are no known phenotypic correlates of *MDF1*, *PGC*, *TOMM6*, *PRICKLE4*, and *FRS3* in the OMIM database; the *TFEB* deletion has been reported in renal cell carcinoma (OMIM \# 600744). The 17q24.3 deletion contained no genes, is located upstream of *SOX9*, does not overlap with previous deletions reported in CMPD, and likely affects expression of SOX9 ([@MCS002766ANTC31]; [@MCS002766ANTC9]; [@MCS002766ANTC33]). The deleted region of Chromosome 17 is a binding site for multiple transcription factors, including SETDB1 and KAP1 that interact with SOX9 in chondrogenesis and sex determination, respectively ([@MCS002766ANTC23]; [@MCS002766ANTC38]). In silico analyses revealed no other rare genetic variant associated with CMPD (see [Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002766/-/DC1)).

It has been suggested that proximity of breakpoints to the *SOX9* locus is correlated with the severity of CMPD ([@MCS002766ANTC16]; [@MCS002766ANTC33]). Interestingly, the breakpoint in our case is 2.3 Mb upstream of *SOX9*, more distal than previously described clusters of Chromosome 17 breakpoint sites in the disease, yet our patient had a severe phenotype of CMPD. [@MCS002766ANTC16] described proximal (50--375 kb) and distal (789--932 kb) clusters of translocation breakpoints in CMPD. More recently, cases with breakpoint clusters farther upstream of *SOX9* (1.03--1.19 Mb) have been reported, creating a third cluster that is often seen in patients with isolated PRS ([@MCS002766ANTC12]; [@MCS002766ANTC11]; [@MCS002766ANTC1]; [@MCS002766ANTC33]). Our case demonstrates a cluster of breakpoints more than 2 Mb upstream of *SOX9* that is associated with severe disease phenotype.

When our patient was readmitted at 2 mo of age for lethargy and respiratory distress, head ultrasound and a brain MRI revealed diffuse ventriculomegaly ([Fig. 1](#MCS002766ANTF1){ref-type="fig"}). Radiographic evaluation of the brain shortly after birth did not reveal ventriculomegaly, and we cannot ascertain when the patient developed this less common manifestation of CMPD. In the absence of signs of increased ICP, no immediate neurosurgical interventions were necessary. [@MCS002766ANTC20] recently reported a case of acquired ventriculomegaly and thinning of the corpus callosum in an 18 mo old born with normal cranial imaging and ACMPD due to a de novo missense mutation in *SOX9*. Ventriculomegaly observed in their patient was likely due to an ex vacuo phenomenon with expected absence of elevated ICP. Our patient showed thinning of the cortical mantle on MRI, but we acknowledge that, without tissue analysis, abnormal neuronal development cannot be established. Regardless, our patient exhibited similar features of normal ICP and communicating hydrocephalus with no indication for CSF diversion, raising the possibility that the ventriculomegaly observed in CMPD may be compensatory and does not necessitate neurosurgical intervention. Further clinical reports are needed to corroborate this hypothesis.

In murine models, mutation of *Sox9* resulted in diminished number of oligodendrocytes in early spinal cord development only to be rescued by *Sox8* expression later in development ([@MCS002766ANTC2]; [@MCS002766ANTC5]). Potentially, a similar mechanism in the cerebrum accounts for ventriculomegaly, thinning of the corpus callosum, hypoplastic olfactory tract, and cerebral atrophy observed in some patients with CMPD. In experiments investigating CNS development in mice and chicks, [@MCS002766ANTC26] observed that induction of SOX9 in neural cells coincides with the presence of neural stem cells that generate neurons and glial cells. Further, loss of *Sox9* expression resulted in ependymal cells adopting a neuroblast identity. Impaired differentiation and ciliation of ependymal cells may account for the ventriculomegaly observed in CMPD, as has been reported in deletion of *SXN27*, a gene that encodes an endosomal sorting factor responsible for trafficking transmembrane receptors in the brain ([@MCS002766ANTC35]). Future studies may investigate this hypothesis.

Although the diagnosis of CMPD/ACMPD is typically made on clinical and radiographic grounds, genetic testing for mutations in *SOX9* or chromosomal rearrangements involving Chromosome 17 should be pursued. Genetic testing identifies pathogenic variants of *SOX9* or chromosomal rearrangements in 95% of cases ([@MCS002766ANTC29]). CMPD is inherited in an autosomal dominant fashion, but most cases are due to de novo genetic alterations. Parental mosaicisim should be considered too. Genetic counseling should be availed to families of patients with this disease. Management of CMPD requires multidisciplinary care. Mortality rate remains high at 77% and 90% by 1 mo old and 2 yr old, respectively; a few patients with less severe phenotypes survive to reproductive age ([@MCS002766ANTC19]; [@MCS002766ANTC18]).

METHODS {#s4}
=======

Sample Collection and Processing {#s4a}
--------------------------------

Following informed consent, cultured amniocytes of the proband were obtained at 21 wk of gestation for prenatal FISH and aCGH; cultured peripheral lymphocytes of the proband\'s parents were also obtained for karyotypes and aCGH studies. Postnatally, the proband\'s peripheral blood sample was obtained for WES.

Cytogenetics {#s4b}
------------

### Proband {#s4b1}

FISH was performed on culture amniocytes using tricolor probes (Vysis Inc.) for DXZ1 locus at Xcen, DYZ3 locus at Ycen, and D18Z1 locus at 18cen, dual-color probes (Vysis Inc.) for 13q14 and D21S259 locus at 21q22, and tricolor probes (Cytocell Inc.) for the *SRY* gene at Yp11.2, DYZ1 locus at Yq12, and DXZ1 locus at Xcen. Chromosome microarray analysis was performed on an array of 180,000 oligonucleotide probes covering the whole genome (Agilent 180K), using high-molecular-weight DNA extracted from the culture amniocytes.

### Proband\'s Parents {#s4b2}

Cultured stimulated peripheral lymphocytes in metaphase were stained using standard technique. In the proband\'s mother, a chromosome microarray analysis was performed on an array of 400,000 oligonucleotide copy number and single-nucleotide polymorphism (SNP) probes covering the whole-genome (Agilent 400K CGH/SNP), using high-molecular-weight DNA extracted from the mother\'s blood specimen. aCGH in proband\'s father was performed similarly (using Agilent 180K and peripheral blood specimen) as described for the proband above.

Exome Sequencing {#s4c}
----------------

Genomic DNA was extracted and purified from the proband\'s peripheral blood using standard protocol at the Yale Center for Genome Analysis. Human genes were isolated by array capture (Roche/Nimlegen MedExome), and these genes were sequenced on the Illumina HiSeq platform as previously described ([@MCS002766ANTC4]; [@MCS002766ANTC13]). Sequence reads were independently mapped to the reference genome (GRCh37/hg19) with BWA-MEM and further processed using GATK Best Practices workflows ([@MCS002766ANTC21]; [@MCS002766ANTC30]; [@MCS002766ANTC8]), including duplication marking, indel realignment, and base quality recalibration, as previously described ([@MCS002766ANTC13]). Using these techniques, mean coverage of the exome is 60×--100×; 96%--97% of the exome is covered at least eight times, and 90%--95% is covered at \>20×. The exome sequencing metrics in our patient are provided in [Supplemental Table 4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002766/-/DC1). Single-nucleotide variants and small indels were called with GATK HaplotypeCaller and annotated using ANNOVAR ([@MCS002766ANTC34]), dbSNP (v138), 1000 Genomes (August 2015), NHLBI Exome Variant Server (EVS), and ExAC (v3) ([@MCS002766ANTC17]). The MetaSVM ([@MCS002766ANTC3]) and the Combined Annotation Dependent Deletion (CADD; v1.3) ([@MCS002766ANTC14]) algorithms were used to predict the deleteriousness of missense variants.

Variant Filtering {#s4d}
-----------------

Variants were filtered for relevance to human disease based on population frequency, likelihood of affecting protein function, and available information in disease-specific databases. The following criteria were used for determining dominant variants in our patient: Remove GATK Variant Score Quality Recalibration (VSQR) \<"PASS"; remove known false positives; remove coverage \<eight reads in proband, remove Genotype Quality (GQ) \<20; remove global minor allele frequency (MAF) \>5 × 10^−5^ in ExAC, 1000 Genomes, and EVS. Loss of function (i.e., frameshift, canonical splice site, stop-gain, and stop-loss) and MetaSVM "D"eleterious missense and CADD ≥20 missense variants were kept. For homozygous/X-linked hemizygous variants, those that met the following criteria were removed: GATK VSQR \<"PASS", known false positives, coverage \<eight reads in proband, GQ \<20, global MAF \>1 × 10^−3^ in ExAC, 1000 Genomes, and EVS. Loss of function, MetaSVM "D"eleterious missense, and CADD ≥20 missense variants were kept.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The t(6;17) translocation in this paper has been submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) under accession number SCV000734849. Raw sequencing data were not deposited in the absence of patient consent but may be available by contacting the authors.
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